Roxana Azimi
Impact in
- Oncology top 10%
- Cancer Immunotherapy and Biomarkers
- Cancer Cells and Metastasis
- CAR-T cell therapy research
- Colorectal Cancer Treatments and Studies
-
- Chronic Lymphocytic Leukemia Research
Papers in
- Oncology 4
- Colorectal Cancer Treatments and Studies 2
- Cancer Immunotherapy and Biomarkers 2
- Cancer Diagnosis and Treatment 1
- HER2/EGFR in Cancer Research 1
-
- Lung Cancer Treatments and Mutations 2
- Co-authors
- Giulia C. Leonardi (2 shared papers)Jonathan W. Riess (2 shared papers)Mark M. Awad (2 shared papers)Justin F. Gainor (2 shared papers)Matthew D. Hellmann (2 shared papers)Hira Rizvi (2 shared papers)Sasha Kravets (1 shared paper)Mehmet Altan (1 shared paper)
- Journals
- Journal of Clinical Oncology (3 papers)Nature (1 paper)Plastic & Reconstructive Surgery Global Open (1 paper)BMJ Case Reports (1 paper)Commentaire (1 paper)
- Partner nations
- United StatesSwedenGermany
In The Last Decade
Roxana Azimi
5 papers receiving 500 citations
Peers
Comparison fields: 5 of 62
- Oncology 347
- Genetics 56
- Cancer Research 74
- Immunology 73
- Pulmonary and Respiratory Medicine 112
Countries citing papers authored by Roxana Azimi
This map shows the geographic impact of Roxana Azimi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roxana Azimi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roxana Azimi more than expected).
Fields of papers citing papers by Roxana Azimi
This network shows the impact of papers produced by Roxana Azimi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roxana Azimi. The network helps show where Roxana Azimi may publish in the future.
Co-authors
The 25 scholars most cited alongside Roxana Azimi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2018 | 258 | |
| 2 | 2017 | 235 | |
| 3 | 2017 | 6 | |
| 4 | 2005 | 1 | |
| 5 | 2017 | 1 | |
| 6 | 2021 | 0 | |
| 7 | 2021 | 0 |
About Roxana Azimi
Roxana Azimi is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Epidemiology, Surgery and Molecular Biology, having authored 7 papers that have together received 501 indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (2 papers), Lung Cancer Treatments and Mutations (2 papers), Cancer Immunotherapy and Biomarkers (2 papers), Epigenetics and DNA Methylation (1 paper), Cancer Diagnosis and Treatment (1 paper), Neuroendocrine Tumor Research Advances (1 paper), Art History and Market Analysis (1 paper) and HER2/EGFR in Cancer Research (1 paper). The work is most often cited by research in Oncology (347 citations), Genetics (56 citations), Cancer Research (74 citations), Immunology (73 citations) and Pulmonary and Respiratory Medicine (112 citations). Roxana Azimi has collaborated with scholars based in United States, Sweden and Germany. Frequent co-authors include Giulia C. Leonardi, Jonathan W. Riess, Mark M. Awad, Justin F. Gainor, Matthew D. Hellmann, Hira Rizvi, Sasha Kravets, Mehmet Altan, Lydia Gedmintas and Suzanne E. Dahlberg. Their work appears in journals such as Journal of Clinical Oncology, Nature, Plastic & Reconstructive Surgery Global Open, BMJ Case Reports and Commentaire.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.